Electra Therapeutics files S-1 for a Nasdaq IPO under ETRA
As seen on the 24/7 Wall St. homepage on August 28, 2026.
Electra Therapeutics files S-1 for a Nasdaq IPO under ETRA
Electra Therapeutics filed its S-1 to list on Nasdaq, with Jefferies, TD Cowen, Evercore ISI and Cantor running the book. Terms and deal size are not set yet, so the pricing amendment is the next thing to watch.
Continue ReadingShow less
Electra Therapeutics has filed an S-1 with the SEC to list on Nasdaq, moving from private biotech to the public markets with Jefferies, TD Cowen, Evercore ISI, and Cantor as joint bookrunners.
No pricing terms, share count, or deal size appear in the initial filing. The pricing amendment will be the first concrete signal of how underwriters are sizing investor demand.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Four bookrunners bring distinct institutional distribution networks, pointing to a wide net for a diversified investor base ahead of pricing.
For investors tracking the biotech IPO pipeline, the next meaningful moment is the amended S-1 that will include a price range and share count. That filing will set the stage for the roadshow and, ultimately, the first day of trading on Nasdaq.